我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
36
2 进行中
药物批准
8
批准总数
监管机构
3
监管机构数
成立时间
N/A
已完成
20
55.6%
尚未招募
2
5.6%
暂停
6
16.7%
终止
Unknown
1
2.8%
撤回
NMPA
National Medical Products Administration
5
PHILIPPINES
Philippines FDA
NPRA
National Pharmaceutical Regulatory Agency
- The global fill-finish manufacturing market reached roughly US$11 billion in 2025, with more than US$27 billion committed to expanding sterile capacity across 2024–2025 alone. - The GLP-1 boom has displaced non-GLP-1 sterile products from existing filling lines, forcing sponsors of antibodies, vaccines, and specialty injectables to seek new manufacturing partners. - Asia-Pacific is building isolator-first, device-aware fill-finish capacity faster than any other region, though equipment qualification lead times of 12–18 months mean most expansions will not be operational until 2027–2028. - The revised EU GMP Annex 1 has raised the regulatory floor globally, making the Contamination Control Strategy a mandatory, inspection-ready system that directly constrains throughput and batch risk.
